The U.S. Senate passed the Affordable Prescriptions for Patients Act (S. 1041) in a unanimous vote, moving legislation aimed at reducing biologics patent thickets toward the House. The bill limits the number of patents a biologics sponsor can assert against a biosimilar during the voluntary “patent dance” under the Biologics Price Competition and Innovation Act. Under the proposed framework, sponsors could list no more than 20 patents in the “patent dance,” which bipartisan sponsors described as a “reasonable” cap. The legislation had languished on the Senate floor for more than a year before the July 21 vote. If enacted, the reform would potentially narrow the scope and duration of patent disputes that can delay biosimilar entry, shifting the litigation leverage between originators and biosimilar developers during a critical regulatory pathway. Industry attention will likely center on how the patent cap is applied and whether the statutory changes accelerate biosimilar launches while maintaining incentives for innovation.